

Response to: 'Mutation in MMP2 gene may result in scleroderma-like skin thickening' by Bader-Meunier *et al*

MMP2 related disease (Multicentric osteolysis, nodulosis and arthropathy—MONA syndrome—OMIM #259600) consists of a continuous clinical spectrum in terms of severity.¹ Even in the same affected individual, different features may present with varying severity (eg, nodulosis may be absent even with severe osteolysis). Till date less than 15 families with *MMP2* mutations have been reported^{2–3} and, therefore, it is likely that the full phenotypical spectrum of *MMP2*-associated conditions has not yet been realised.

In this context, this report from Bader-Meunier *et al*⁴ of a patient with biallelic *MMP2* mutation and scleroderma-like skin thickening in addition to the other known features of MONA syndrome is instructive. Notably, most previous reports of individuals with *MMP2* mutations are of young children and skin thickening can be a progressive feature. In future it will be interesting to learn about evolution of the phenotype in previously reported cases or the adult phenotype of this group of conditions.

We reported two families with 8q22.1 duplications and Leri's pleonostosis (LP) and provided evidence that LP could also be considered as a transforming growth factor (TGF)-betopathy.⁵ Interestingly, skin thickening was seen in one of our families with LP but was absent in all the members of the other family. Our previous work and the report of Bader-Meunier *et al* provides further support that presence of skin thickening can be a clue towards monogenic TGF-betopathies. However, skin thickening may be a more variable feature of those TGF-betopathies where it is not part of the core phenotype (cf Stiff skin syndrome—OMIM #184900).⁶

Recognising additional monogenic causes of scleroderma due to alterations in the TGF-beta pathway strengthens the possibility that rare variants in genes encoding members of this pathway as being causally linked with more common forms of scleroderma.

Siddharth Banka,¹ William G Newman²

¹Manchester Centre for Genomic Medicine, Institute of Human Development, Manchester, UK

²Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK
Correspondence to Dr Siddharth Banka, Manchester Centre for Genomic Medicine, Institute of Human Development, St Mary's Hospital, Manchester M13 9WL, UK; siddharth.banka@manchester.ac.uk

Twitter Follow Siddharth Banka at @smbanka

Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.



CrossMark

To cite Banka S, Newman WG. *Ann Rheum Dis* 2016;**75**:e2.

Received 7 September 2015

Accepted 10 September 2015

Published Online First 13 October 2015



► <http://dx.doi.org/10.1136/annrheumdis-2015-208182>

Ann Rheum Dis 2016;**75**:e2. doi:10.1136/annrheumdis-2015-208538

REFERENCES

- Zankl A, Pachman L, Poznanski A, *et al*. Torg Syndrome Is Caused by Inactivating Mutations in *MMP2* and Is Allelic to NAO and Winchester Syndrome. *J Bone Miner Res* 2007;**22**:329–33.
- Ekbote AV, Danda S, Zankl A, *et al*. Patient with mutation in the matrix metalloproteinase 2 (*MMP2*) gene—a case report and review of the literature. *J Clin Res Pediatr Endocrinol* 2014;**6**:40–6.
- Azzollini J, Rovina D, Gervasini C, *et al*. Functional characterisation of a novel mutation affecting the catalytic domain of *MMP2* in siblings with multicentric osteolysis, nodulosis and arthropathy. *J Hum Genet* 2014;**59**: 631–7.
- Bader-Meunier B, *et al*. Mutation in *MMP2* gene may result in scleroderma-like skin thickening. *Ann Rheum Dis* 2016;**75**:e1.
- Banka S, Cain SA, Carim S, *et al*. Leri's pleonostosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing *GDF6* and *SDC2* and provides insight into systemic sclerosis pathogenesis. *Ann Rheum Dis* 2015;**74**: 1249–56.
- Loeys BL, Gerber EE, Riegert-Johnson D, *et al*. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. *Sci Transl Med* 2010;**2**:23ra20.